Do Allergy Shots Really Work? Myths, Evidence and Honest Answers

Individual response to allergy shots varies substantially, and the most common reasons for poor outcomes are identifiable and often preventable. Incorrect allergen identification is the leading cause — up to 30% of patients have discordant results between skin prick testing and specific IgE blood tests, meaning treatment may target allergens that aren't actually driving symptoms. Other modifiable factors include subtherapeutic dosing (failing to reach the 5-20 microgram major allergen maintenance target), premature discontinuation before 3 years, and having a mixed-rhinitis condition with a non-allergic vasomotor component that immunotherapy cannot address. Predictors of better response include monosensitization, younger age at treatment start, and shorter disease duration. Your allergist can assess these factors to estimate your individual likelihood of benefit before committing to treatment.

Most patients who are going to respond to allergy shots notice some degree of symptom improvement within 6-12 months of starting, with more substantial improvement over years 2-3. Useful benchmarks to track include: daily antihistamine or nasal spray use (should decrease over time), the severity and duration of your allergy seasons, sleep quality during peak pollen season, and missed work or school days. Your allergist may use standardized questionnaires like the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) to measure progress objectively. Per the AAAAI/ACAAI Practice Parameter, if there is no clinically meaningful improvement after one full year of adequate maintenance dosing — and allergen selection and dosing have been verified as appropriate — reassessment is warranted. Not seeing improvement in the first few months, however, is expected and should not prompt early discontinuation.

Allergy shots temporarily worsen local symptoms during the build-up phase for some patients — redness, swelling, and itching at the injection site are common and expected in 30-80% of patients. Some patients experience a temporary worsening of nasal symptoms during early build-up as the immune system is challenged. These are normal parts of the desensitization process, not signs that shots are failing or causing harm. True worsening of underlying allergy disease from immunotherapy is not a documented outcome in the clinical literature. In fact, the evidence suggests the opposite: allergy shots reduce the development of new sensitizations and lower the risk of allergic rhinitis progressing to asthma in children. If your symptoms seem significantly worse during treatment, this should be discussed with your allergist to rule out inadequate dose adjustments or missed infections driving the symptoms.

Allergy shots are unlikely to work in several well-documented scenarios. Non-IgE-mediated conditions — such as vasomotor rhinitis, irritant-triggered rhinitis, or non-allergic rhinitis — are not driven by the IgE pathway that immunotherapy targets, and shots will not help. Allergy shots also do not work for food allergies (oral immunotherapy is a separate approach for food-specific desensitization). Patients with uncontrolled or severe asthma are contraindicated from SCIT due to elevated anaphylaxis risk. Beta-blocker medications complicate epinephrine treatment of reactions and are a relative contraindication. Finally, shots are not useful when the wrong allergens are being treated — if skin prick testing identified a trigger that specific IgE bloodwork does not confirm, the immunotherapy may have no relevant target. A board-certified allergist can rule out these contraindications before starting treatment.

The AAAAI/ACAAI Joint Task Force Practice Parameter specifies that the minimum duration before declaring allergy shots ineffective is one year of maintenance dosing at an adequate dose — not one year from the first injection. The build-up phase (typically 3-6 months) is followed by at least 6-12 months of maintenance before a fair assessment is possible. Patients who stop before reaching this milestone based on early lack of improvement often discontinue prematurely; the immune retraining process takes time, and measurable symptom improvement typically lags several months behind the underlying immunologic changes. If after a full year of adequate maintenance dosing there is still no clinically meaningful improvement, and allergen selection and dosing have been reassessed, then discontinuation or switching to an alternative approach is reasonable.

Allergy shots are definitively not a placebo — the evidence against this is robust. All major clinical trials use genuine sham injections (saline) as the placebo control, meaning patients in both groups receive injections and experience the same expectation of benefit. The pooled effect size from 51 such trials — standardized mean difference of -0.73 for symptom reduction — is measured against these real placebo controls, not against 'no treatment.' Additionally, the molecular evidence of treatment effect is measurable: IgG4 blocking antibody levels rise 10-100 fold in treated patients, regulatory T-cell populations expand, and IgE-mediated mast cell reactivity diminishes — objective biological markers that confirm immune reprogramming is occurring. The disease-modifying benefits persisting 3-12 years after stopping treatment are also inconsistent with a placebo mechanism.

Six months is generally too early to accurately judge whether allergy shots are working. Most patients still in build-up or just entering maintenance at 6 months have not yet accumulated enough allergen exposure to see meaningful immune tolerance. The immunologic changes — rising IgG4, expanding regulatory T cells, declining IgE sensitivity — accumulate gradually over 12-24 months of treatment. Per the AAAAI/ACAAI guidelines, the minimum assessment period before considering discontinuation due to lack of efficacy is one year of adequate maintenance dosing. If cost, time, or significant side effects are driving consideration of stopping, those are valid reasons to discuss alternatives with your allergist. But stopping because symptoms haven't improved by month 6 is almost always premature and will result in either a need to restart from scratch or forgoing potential long-term benefit entirely.